America’s Blood Centers (ABC) has provided comments to the U.S. Food and Drug
Administration’s (FDA) Blood Product Advisory Committee (BPAC) ahead of the
November 4th meeting. In the comments, the committee received an update of the
“ongoing work” of ABC member blood centers during the COVID-19 pandemic
and the challenges facing them and the blood community in maintaining the nation’s
blood supply. The comments also urged the FDA to make temporary guidances
brought on by the public health emergency permanent [and] to adopt protocols or
generic licensing for convalescent plasma (CP) as a part of preparedness strategies
for “the next novel disease.”
Posted in Letters